中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
Chinese Journal of Oncology
2015年
11期
833-836
,共4页
乳腺肿瘤%药物疗法%受体,胰岛素样生长因子1%受体,雌激素%治疗结果
乳腺腫瘤%藥物療法%受體,胰島素樣生長因子1%受體,雌激素%治療結果
유선종류%약물요법%수체,이도소양생장인자1%수체,자격소%치료결과
Breast neoplasms%Drug therapy%Receptors,type 1 insulin-like growth factor%Receptors,estrogen%Treatment outcome
目的 探讨胰岛素样生长因子1受体(IGF1R)和雌激素受体(ER)表达与乳腺癌新辅助化疗疗效的关系.方法 采用免疫组化方法,对139例接受TE方案(多西他赛+表柔比星)新辅助化疗的乳腺癌患者化疗前肿瘤穿刺组织进行IGF1R表达及ER表达检测,分析IGF1R和ER表达与化疗疗效达到病理完全缓解(pCR)间的关系.结果 139例乳腺癌患者中,IGF1R高表达率为45.3％ (63/139),ER阳性率为62.6％(87/139).ER阳性和ER阴性患者中IGF1R高表达率分别为54.0％ (47/87)和30.8％(16/52),差异有统计学意义(P＜0.01).139例乳腺癌患者接受TE方案新辅助化疗后,pCR率为10.1％(14/139).ER阴性和ER阳性患者中pCR率分别为19.2％(10/52)和4.6％(4/87),差异有统计学意义(P＜0.05).IGF1R低表达和IGF1R高表达患者中pCR率分别为10.5％ (8/76)和9.5％(6/63),差异无统计学意义(P＞0.05).ER阴性且IGF1R高表达患者中pCR率为31.2％(5/16),明显高于全组pCR率,差异有统计学意义(P＜0.01).结论 ER阴性且IGF1R高表达乳腺癌患者对TE方案新辅助化疗更为敏感,pCR率明显高于其他患者.
目的 探討胰島素樣生長因子1受體(IGF1R)和雌激素受體(ER)錶達與乳腺癌新輔助化療療效的關繫.方法 採用免疫組化方法,對139例接受TE方案(多西他賽+錶柔比星)新輔助化療的乳腺癌患者化療前腫瘤穿刺組織進行IGF1R錶達及ER錶達檢測,分析IGF1R和ER錶達與化療療效達到病理完全緩解(pCR)間的關繫.結果 139例乳腺癌患者中,IGF1R高錶達率為45.3％ (63/139),ER暘性率為62.6％(87/139).ER暘性和ER陰性患者中IGF1R高錶達率分彆為54.0％ (47/87)和30.8％(16/52),差異有統計學意義(P＜0.01).139例乳腺癌患者接受TE方案新輔助化療後,pCR率為10.1％(14/139).ER陰性和ER暘性患者中pCR率分彆為19.2％(10/52)和4.6％(4/87),差異有統計學意義(P＜0.05).IGF1R低錶達和IGF1R高錶達患者中pCR率分彆為10.5％ (8/76)和9.5％(6/63),差異無統計學意義(P＞0.05).ER陰性且IGF1R高錶達患者中pCR率為31.2％(5/16),明顯高于全組pCR率,差異有統計學意義(P＜0.01).結論 ER陰性且IGF1R高錶達乳腺癌患者對TE方案新輔助化療更為敏感,pCR率明顯高于其他患者.
목적 탐토이도소양생장인자1수체(IGF1R)화자격소수체(ER)표체여유선암신보조화료료효적관계.방법 채용면역조화방법,대139례접수TE방안(다서타새+표유비성)신보조화료적유선암환자화료전종류천자조직진행IGF1R표체급ER표체검측,분석IGF1R화ER표체여화료료효체도병리완전완해(pCR)간적관계.결과 139례유선암환자중,IGF1R고표체솔위45.3％ (63/139),ER양성솔위62.6％(87/139).ER양성화ER음성환자중IGF1R고표체솔분별위54.0％ (47/87)화30.8％(16/52),차이유통계학의의(P＜0.01).139례유선암환자접수TE방안신보조화료후,pCR솔위10.1％(14/139).ER음성화ER양성환자중pCR솔분별위19.2％(10/52)화4.6％(4/87),차이유통계학의의(P＜0.05).IGF1R저표체화IGF1R고표체환자중pCR솔분별위10.5％ (8/76)화9.5％(6/63),차이무통계학의의(P＞0.05).ER음성차IGF1R고표체환자중pCR솔위31.2％(5/16),명현고우전조pCR솔,차이유통계학의의(P＜0.01).결론 ER음성차IGF1R고표체유선암환자대TE방안신보조화료경위민감,pCR솔명현고우기타환자.
Objective To detect the expression of IGF1R and estrogen receptor, and to explore the relationship between their expression and the pathological complete response (pCR) rate of neoadjuvant chemotherapy (docetaxel plus epirubicin) in breast cancer patients.Methods We selected 139 women with breast cancer who underwent neoadjuvant chemotherapy (docetaxel plus epirubicin), and detected the expression of IGF1R and estrogen receptor in the samples taken before chemotherapy by Immunohistochemistry.The association between their expression and pCR rate of neoadjuvant chemotherapy was analyzed.Results Among the 139 cases, IGF1R was highly expressed in 45.3％ (63/139) cases, and ER was positively expressed in 62.6％ (87/139) cases.IGF1R was highly expressed in 54.0％ (47/87) of the ER+ cases, significantly higher than that of ER-cases (30.8％ ,P＜0.01).The overall pCR rate of all the 139 patients who received docetaxel plus epirubicin as neoadjuvant chemotherapy was 10.1％ (14/139).The pCR rate was 19.2％ (10/52) of the ER-patients and 4.6％ (4/87) of the ER+ patients (P＜0.05).The pCR rate was 10.5％ (8/76) in the patients with low IGF1R expression and 9.5％ (6/63) in the patients with high IGF1R expression (P＞0.05).The patients with negative expression of ER and high expression of IGF1R showed the highest pCR rate (31.2％, P＜0.01).Conclusions Breast cancer patients with negative expression of ER and high expression of IGF1R are more sensitive to neoadjuvant chemotherapy of docetaxel plus epirubicin, and their pCR rate is significantly higher than that of other patients.
